|
MechanismTXA2 synthase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date27 Mar 1992 |
[Translation] Pharmacokinetics of Ozagrel Hydrochloride Tablets in Humans
本试验的目的是在健康志愿受试者中研究通辽市华邦药业有限公司提供的盐酸奥扎格雷片,完成单次、多次给药药动学试验,通过建立血样中奥扎格雷及其代谢物的方法学和检测血浆样本,得到相应的药动学参数,了解盐酸奥扎格雷片在人体内动态变化的规律,多次连续给药体内蓄积情况,为临床合理用药提供依据。
[Translation] The purpose of this study is to study the single-dose and multiple-dose pharmacokinetic studies of Ozagrel Hydrochloride Tablets provided by Tongliao Huabang Pharmaceutical Co., Ltd. in healthy volunteers. By establishing the methodology of Ozagrel and its metabolites in blood samples and detecting plasma samples, the corresponding pharmacokinetic parameters are obtained to understand the dynamic changes of Ozagrel Hydrochloride Tablets in the human body and the accumulation in the body after multiple continuous administrations, so as to provide a basis for rational clinical drug use.
100 Clinical Results associated with Nankai Yungong Pharmaceutical Co.,Ltd.
0 Patents (Medical) associated with Nankai Yungong Pharmaceutical Co.,Ltd.
100 Deals associated with Nankai Yungong Pharmaceutical Co.,Ltd.
100 Translational Medicine associated with Nankai Yungong Pharmaceutical Co.,Ltd.